US FDA places clinical hold on Tenaya Therapeutics' gene therapy
07/11/2025 21:32
Nov 7 (Reuters) - The U.S. Food and Drug Administration has placed a clinical hold on Tenaya Therapeutics' TNYA.O trial of its experimental gene therapy for a type of inherited heart disease, the company said on Friday. (Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027